Meeting Coverage

Hepatitis Liver Cancer Rates With Interferon-Free Regimens in HIV/HCV

Liver Cancer Rates With Interferon-Free Regimens in HIV/HCV

The incidence of hepatocellular carcinoma after sustained virological response has not increased with the widespread use of all oral direct antivirals regimens as suggested in previous studies, according to a new study.

Hepatitis French Study Points to Eradication of HIV-HCV Coinfection

French Study Points to Eradication of HIV-HCV Coinfection

Prevalence of active HIV-HCV coinfection may decrease to 1.1% in France over the next decade.

CROI 2017 Latent HIV May Exist in Both Resting and Non-Resting CD4 T cells

Latent HIV May Exist in Both Resting and Non-Resting CD4 T cells

Researchers quantify inducible virus in long-term suppressed patients that was missed by the gold standard assay that measures the latent reservoir.

CROI 2017 New Study Links Darunavir to Increased Risk for CVD

New Study Links Darunavir to Increased Risk for CVD

Study looking at the use of 2 frequently used protease inhibitors (atazanavir and darunavir) is suggesting that cumulative use of darunavir may be independently associated with a small but gradually increasing cardiovascular disease (CVD) risk.

HIV/AIDS Vaginal Microbiota May Affect Tenofovir Applied Intravaginally

Vaginal Microbiota May Affect Tenofovir Applied Intravaginally

New study suggests that the vaginal microbiome may modify tenofovir delivery.

CROI 2017 Novel mRNA Zika Virus Vaccine Shows Rapid and Durable Protection

Novel mRNA Zika Virus Vaccine Shows Rapid and Durable Protection

A new vaccine candidate uses an mRNA platform to deliver safe, low doses of a vaccine that offers high levels of sustained protection against Zika virus.

CROI 2017 Investigational 2-Drug HIV Regimen Showing Promise

Investigational 2-Drug HIV Regimen Showing Promise

Investigational combination of a once-daily 2-drug regimen of dolutegravir plus rilpivirine may be as effective as a 3- or 4-drug current antiretroviral regimen in HIV-1-infected patients.

CROI 2017 Multiple Viral Load Value Testing May Better Inform HIV Transmission Potential

Multiple Viral Load Value Testing May Better Inform HIV Transmission Potential

Viral loads can fluctuate over time depending on patients' access and response to HIV treatment, their medication adherence behavior, and care status.

CROI 2017 Potential New Drug Option for Treatment-Naïve HIV-1 Patients

Potential New Drug Option for Treatment-Naïve HIV-1 Patients

The once-daily dosing doravirine appears to have similar efficacy and to be non-inferior to once-daily ritonavir-boosted darunavir (DRV+r) on a background of 2 NRTIs in HIV-1 treatment-naïve adults.

CROI 2017 Study Supports Current Prevention Interventions for Zika Exposure

Study Supports Current Prevention Interventions for Zika Exposure

The current sexual prevention guidelines recommend that men use condoms or abstain from sex for 6 months after Zika virus exposure. Now there are strong data to support these guidelines.